TY - JOUR
T1 - Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset
T2 - Japan Alteplase Clinical Trial (J-ACT)
AU - Yamaguchi, Takenori
AU - Mori, Etsuro
AU - Minematsu, Kazuo
AU - Nakagawara, Jyoji
AU - Hashi, Kazuo
AU - Saito, Isamu
AU - Shinohara, Yukito
PY - 2006/7
Y1 - 2006/7
N2 - BACKGROUND AND PURPOSE - Based on previous studies comparing different recombinant tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is lower than the internationally approved dosage of 0.9 mg/kg, aiming to assess the efficacy and safety of alteplase in acute ischemic stroke for the Japanese. METHODS - Our prospective, multicenter, single-arm, open-label trial was designed with a target sample size of 100 patients. The primary end points were the proportion of patients with a modified Rankin Scale (mRS) score of 0 to 1 at 3 months and the incidence of symptomatic intracranial hemorrhage (sICH) within 36 hours. Thresholds for these end points were determined by calculating 90% CIs of weighted averages derived from published reports. The protocol was defined according to the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA stroke study with slight modifications. RESULTS - Among the 103 patients enrolled, 38 had an mRS of 0 to 1 at 3 months; this proportion (36.9%) exceeded the predetermined threshold of 33.9%. sICH within 36 hours occurred in 6 patients; this incidence (5.8%) was lower than the threshold of 9.6%. CONCLUSIONS - In patients receiving 0.6 mg/kg alteplase, the outcome and the incidence of sICH were comparable to published data for 0.9 mg/kg. These findings indicate that alteplase, when administered at 0.6 mg/kg to Japanese patients, might offer a clinical efficacy and safety that are compatible with data reported in North America and the European Union for a 0.9 mg/kg dose.
AB - BACKGROUND AND PURPOSE - Based on previous studies comparing different recombinant tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is lower than the internationally approved dosage of 0.9 mg/kg, aiming to assess the efficacy and safety of alteplase in acute ischemic stroke for the Japanese. METHODS - Our prospective, multicenter, single-arm, open-label trial was designed with a target sample size of 100 patients. The primary end points were the proportion of patients with a modified Rankin Scale (mRS) score of 0 to 1 at 3 months and the incidence of symptomatic intracranial hemorrhage (sICH) within 36 hours. Thresholds for these end points were determined by calculating 90% CIs of weighted averages derived from published reports. The protocol was defined according to the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA stroke study with slight modifications. RESULTS - Among the 103 patients enrolled, 38 had an mRS of 0 to 1 at 3 months; this proportion (36.9%) exceeded the predetermined threshold of 33.9%. sICH within 36 hours occurred in 6 patients; this incidence (5.8%) was lower than the threshold of 9.6%. CONCLUSIONS - In patients receiving 0.6 mg/kg alteplase, the outcome and the incidence of sICH were comparable to published data for 0.9 mg/kg. These findings indicate that alteplase, when administered at 0.6 mg/kg to Japanese patients, might offer a clinical efficacy and safety that are compatible with data reported in North America and the European Union for a 0.9 mg/kg dose.
KW - Stroke, acute
KW - Thrombolytic therapy
KW - Tissue plasminogen activator
UR - http://www.scopus.com/inward/record.url?scp=33745963843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745963843&partnerID=8YFLogxK
U2 - 10.1161/01.STR.0000227191.01792.e3
DO - 10.1161/01.STR.0000227191.01792.e3
M3 - Article
C2 - 16763187
AN - SCOPUS:33745963843
VL - 37
SP - 1810
EP - 1815
JO - Stroke
JF - Stroke
SN - 0039-2499
IS - 7
ER -